ELIAS TZELEPIS
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism MIAMI, FL NPI 1013203173
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism FL DEXCOM, INC. All categories
General Payments — all program years on this page
$20,296.92
- Category: General Payments
- Program years: PY2018–2024
- Record count: 924
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $3,258.99 across 122 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $3,250.66 | 121 |
| Education | $8.33 | 1 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| DEXCOM, INC. | $598.54 | 12 |
| Lilly USA, LLC | $538.34 | 28 |
| Corcept Therapeutics | $250.09 | 7 |
| Alexion Pharmaceuticals, Inc. | $195.46 | 4 |
| Abbott Laboratories | $189.17 | 8 |
| Kyowa Kirin, Inc. | $188.54 | 4 |
| Novo Nordisk AS | $102.74 | 5 |
| CHIESI USA, INC. | $93.99 | 1 |
| SANOFI-AVENTIS U.S. LLC | $93.56 | 4 |
| ABBVIE INC. | $88.55 | 5 |
| Xeris Pharmaceuticals, Inc. | $86.99 | 4 |
| RECORDATI_RARE_DISEASES_INC. | $73.33 | 3 |
| Amneal Pharmaceuticals LLC | $60.56 | 3 |
| Amgen Inc. | $57.96 | 4 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $56.02 | 2 |
| Esperion Therapeutics, Inc. | $55.79 | 3 |
| Bayer HealthCare Pharmaceuticals Inc. | $52.91 | 2 |
| Ascensia Diabetes Care US Inc. | $50.33 | 2 |
| MannKind Corporation | $49.24 | 2 |
| BETA BIONICS, INC. | $47.70 | 2 |
| Medtronic, Inc. | $47.22 | 2 |
| IBSA Pharma Inc. | $46.89 | 3 |
| Astellas Pharma US Inc | $43.35 | 2 |
| Antares Pharma, Inc. | $35.77 | 2 |
| Amphastar Pharmaceuticals, Inc. | $33.22 | 2 |
| Ascendis Pharma Inc | $27.05 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $23.98 | 1 |
| Nevro Corp. | $22.14 | 1 |
| Tandem Diabetes Care, Inc. | $20.01 | 1 |
| Radius Health, Inc. | $17.57 | 1 |
| TheracosBio, LLC | $11.98 | 1 |
By program year
Records — PY2024 (122)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.